Compare · CLOV vs ILMN
CLOV vs ILMN
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.56B, about 12.2x CLOV ($2.02B).
- ILMN has been more active in the news (22 items in the past 4 weeks vs 4 for CLOV).
- ILMN has more recent analyst coverage (25 ratings vs 12 for CLOV).
- Company
- Clover Health Investments Corp.
- Illumina Inc.
- Price
- $3.88+1.17%
- $158.70-2.20%
- Market cap
- $2.02B
- $24.56B
- 1M return
- +37.66%
- -
- 1Y return
- +29.60%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 4
- 22
- Recent ratings
- 12
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CLOV
- CEO, Counterpart Health Wai Conrad sold $879,500 worth of shares (220,426 units at $3.99) as part of a pre-agreed trading plan (SEC Form 4)
- Director Edwards Carladenise Armbrister sold $229,687 worth of shares (67,160 units at $3.42), decreasing direct ownership by 19% to 285,432 units (SEC Form 4)
- Interim CFO Thornton Joseph Clay covered exercise/tax liability with 16,942 shares, decreasing direct ownership by 1% to 1,217,584 units (SEC Form 4) (withholding obligation)
- Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 144 filed by Clover Health Investments Corp.
- CEO of Clover Care Services Priest Brady Patrick sold $345,097 worth of shares (98,039 units at $3.52), decreasing direct ownership by 5% to 2,040,222 units (SEC Form 4)
- Chief Executive Officer Toy Andrew covered exercise/tax liability with 85,704 shares, decreasing direct ownership by 0.86% to 9,923,301 units (SEC Form 4) (withholding obligation)
- SEC Form 10-Q filed by Clover Health Investments Corp.
- Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Clover Health Reports First Quarter 2026 Results
Latest ILMN
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits